Cetuximab as First-line Treatment for Metastatic Colorectal Cancer: Caution With Interpretation of Cost-Effectiveness Results Toward Medical Decision Making

被引：0
|
作者：
Franken, Mira D. [1 ]
Koopman, Miriam [1 ]
van Oijen, Martijn G. H. [2 ]
机构：
[1] Univ Med Ctr Utrecht, Dept Med Oncol, Utrecht, Netherlands
[2] Univ Amsterdam, Acad Med Ctr, Dept Med Oncol, Meibergdreef 9, NL-1105 AZ Amsterdam, Netherlands
来源：
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS | 2016年 / 39卷 / 02期
关键词：
D O I：
10.1097/COC.0000000000000253
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：214 / 214
页数：1
相关论文
共 50 条
  • [31] Atezolizumab with chemotherapy in first-line treatment for metastatic urothelial cancer: a cost-effectiveness analysis
    Zhang, Peng-Fei
    Wen, Feng
    Wu, Qiu-Ji
    Li, Qiu
    JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH, 2022, 11 (14) : 1021 - 1030
  • [32] COST-EFFECTIVENES OF CETUXIMAB IN FIRST-LINE TREATMENT OF PATIENTS WITH METASTATIC COLORECTAL CANCER IN BELGIUM AND THE NETHERLANDS
    Krol, M.
    Ovcinnikova, O.
    von Hohnhorst, P.
    Jarrett, J.
    VALUE IN HEALTH, 2015, 18 (07) : A464 - A464
  • [33] Cost-Effectiveness of Adding Cetuximab to Platinum-Based Chemotherapy for First-Line Treatment of Recurrent or Metastatic Head and Neck Cancer
    Hannouf, Malek B.
    Sehgal, Chander
    Cao, Jeffrey Q.
    Mocanu, Joseph D.
    Winquist, Eric
    Zaric, Gregory S.
    PLOS ONE, 2012, 7 (06):
  • [34] CETUXIMAB IN COMBINATION WITH XELIRI OR XELOX IN FIRST-LINE TREATMENT OF METASTATIC COLORECTAL CANCER
    Ocvirk, Janja
    Rebersek, Martina
    Boc, Marko
    Mesti, Tanja
    Moltara, Maja Ebert
    ANNALS OF ONCOLOGY, 2011, 22 : v96 - v96
  • [35] First-line targeted therapies in the treatment of metastatic colorectal cancer - role of cetuximab
    Tonini, Giuseppe
    Calvieri, Alice
    Vincenzi, Bruno
    Santini, Daniele
    ONCOTARGETS AND THERAPY, 2009, 2 : 73 - 82
  • [36] COST EFFECTIVENESS OF CETUXIMAB AND PANITUMUMAB FOR FIRST-LINE RAS WT METASTATIC COLORECAL CANCER
    Tikhonova, I
    Hoyle, M.
    Snowsill, T.
    Crathorne, L.
    Varley-Campbell, J.
    Peters, J.
    Briscoe, S.
    Bond, M.
    Huxley, N.
    VALUE IN HEALTH, 2016, 19 (03) : A154 - A154
  • [37] CONSEQUENCES OF BIOMARKER ANALYSIS ON THE COST-EFFECTIVENESS OF CETUXIMAB IN COMBINATION WITH IRINOTECAN BASED CHEMOTHERAPY FOR FIRST-LINE TREATMENT OF METASTATIC COLORECTAL CANCER. STRATIFIED MEDICINE AT WORK?
    Harty, G. T.
    Jarrett, J.
    Jofre-Bonet, M.
    VALUE IN HEALTH, 2015, 18 (07) : A456 - A456
  • [38] Cost-effectiveness analysis of cetuximab combined with chemotherapy as a first-line treatment for patients with RAS wild-type metastatic colorectal cancer based on the TAILOR trial
    Wang, Huijuan
    Huang, Lingfei
    Gao, Peng
    Zhu, Zhengyi
    Ye, Weifeng
    Ding, Haiying
    Fang, Luo
    BMJ OPEN, 2020, 10 (02):
  • [39] Cetuximab in first line treatment of metastatic colorectal cancer
    Barone, Carlo
    Belisari, Andrea
    Ciardiello, Fortunato
    D'Angiolella, Lucia
    Furneri, Gianluca
    Mantovani, Lorenzo
    Normanno, Nicola
    Piacentini, Patrizio
    Pinto, Carmine
    FARMECONOMIA-HEALTH ECONOMICS AND THERAPEUTIC PATHWAYS, 2012, 13 : 3 - 78
  • [40] Cost-effectiveness of first-line treatments for patients with KRAS wild-type metastatic colorectal cancer
    Ewara, E. M.
    Zaric, G. S.
    Welch, S.
    Sarma, S.
    CURRENT ONCOLOGY, 2014, 21 (04) : E541 - E550
12345